Home

Elisabeth Åvall Lundqvist

Professor of Clinical Oncology focusing gynecological oncology

Gynaecological Cancer

My research interest is cervical cancer and how we can extend the survival rate through more effective treatments but without paying the price in the form of unwanted side effects

Research Co-operation

CABSOE

  • Prof Gillian Thomas, Toronto and Linköpings University
  • Prof Preben Kjölhede, Linköpings University
  • Elisabet Classon, PhD, Linköpings University

STROVA

  • Sara Corvigno, PhD student, Karolinska Institutet
  • Hanna Dahlstrand, main supervisor, Karolinska Institutet
  • Arne Östman, co-supervisor, Karolinska Institutet

RASHEC

  • Sara Salehi, PhD student, Karolinska Institutet
  • Henrik Falconer, main supervisor, Karolinska Institutet

2024

Suzanne T. Witt, Alana Brown, Laura Gravelsins, Maria Engström, Elisabet Classon, Nina Lykke, Elisabeth Åvall Lundqvist, Elvar Theodorsson, Jan Ernerudh, Preben Kjölhede, Gillian Einstein (2024) Gray matter volume in women with the BRCA mutation with and without ovarian removal: evidence for increased risk of late-life Alzheimer's disease or dementia Menopause: The Journal of the North American Menopause, Vol. 31, p. 608-616 (Article in journal) Continue to DOI
Kristina Engvall, Hanna Uvdal, Niclas Björn, Elisabeth Åvall Lundqvist, Henrik Green (2024) Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing npj Precision Oncology, Vol. 8, Article 102 (Article in journal) Continue to DOI
Pernilla Dahm-Kahler, Angelique Floter Radestad, Erik Holmberg, Christer Borgfeldt, Maria Bjurberg, Camilla Skold, Kristina Hellman, Preben Kjölhede, Karin Stalberg, Elisabeth Åvall Lundqvist (2024) Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study Gynecologic Oncology, Vol. 186, p. 69-76 (Article in journal) Continue to DOI
Felicia Roncolato, Madeleine T. King, Rachel L. O'Connell, Yeh Chen Lee, Florence Joly, Felix Hilpert, Anne Lanceley, Yoshio Yoshida, Jane Bryce, Paul Donnellan, Amit Oza, Elisabeth Åvall Lundqvist, Jonathan S. Berek, Jonathan A. Ledermann, Dominique Berton, Jalid Sehouli, Marie-Christine Kaminsky, Martin R. Stockler, Michael Friedlander (2024) Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer Gynecologic Oncology, Vol. 185, p. 128-137 (Article in journal) Continue to DOI
Diana Zach, Pernille T. Jensen, Henrik Falconer, Zuzana Kolkova, Katja Stenstrom Bohlin, Preben Kjölhede, Elisabeth Åvall Lundqvist, Angelique Floter Radestad (2024) Anxiety and depression among women with newly diagnosed vulvar cancer - A nationwide longitudinal study Acta Obstetricia et Gynecologica Scandinavica, Vol. 103, p. 396-406 (Article in journal) Continue to DOI
Henrik Green.

Nerve damage from cancer treatment can be predicted

Many women treated for breast cancer using taxanes, a type of cytostatic drug, often experience side effects in the nervous system. Researchers at LiU have developed a tool that can predict the risk level for each individual.

Tags